Tonix Pharmaceuticals Provides Update On Development of Its Single Dose Live Attenuated Virus Vaccine Candidate For Mpox: Company Says TNX-801 Will Provide Long-term Protection From Mpox & Smallpox With One Dose
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has provided an update on the development of its single-dose live attenuated virus vaccine candidate, TNX-801, which aims to offer long-term protection from Mpox and Smallpox with just one dose.
August 16, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals announced progress on TNX-801, a single-dose vaccine candidate for Mpox and Smallpox, which could provide long-term protection.
The development of TNX-801 as a single-dose vaccine for Mpox and Smallpox is a significant advancement. If successful, it could lead to increased investor confidence and a positive impact on TNXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100